We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis (MaSep)

This study is currently recruiting participants.
Verified November 2016 by Dr. med. Ursula Hoffmann, Universitätsmedizin Mannheim
Sponsor:
ClinicalTrials.gov Identifier:
NCT01535534
First Posted: February 17, 2012
Last Update Posted: November 23, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr. med. Ursula Hoffmann, Universitätsmedizin Mannheim
February 14, 2012
February 17, 2012
November 23, 2016
January 2012
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01535534 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
Evaluation of Mediators of Inflammation, Prognostic Markers and Genetic Polymorphisms in Patients With Sepsis
During the past years many investigators have focused on the immunological changes in sepsis disease, and great attention has been paid to the development of practicable means of immunomonitoring. Little is known about diagnostic and prognostic vascular biomarkers during the time course of patients with sepsis.

Primary Outcome Measures:

New diagnostic and prognostic markers for septic patients

Estimated Enrollment: 300 patients Study Start Date: January 2012 Estimated Study Completion Date: open Estimated Primary Completion Date: open

Intervention Details:

Procedure: vein puncture comparison of different inflammatory markers in the blood of septic patients

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Peripheral blood samples
Probability Sample
Patients suffering from sepsis
Sepsis
Not Provided
Not Provided
Behnes M, Bertsch T, Lepiorz D, Lang S, Trinkmann F, Brueckmann M, Borggrefe M, Hoffmann U. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014 Sep 5;18(5):507. doi: 10.1186/s13054-014-0507-z.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
July 2017
Not Provided

Inclusion Criteria:

  • SIRS-Criteria
  • Proven Infection
  • One sepsis-induced organ-failure
  • Adults < 18 years old

Exclusion Criteria:

  • Anemia
  • Pregnancy
  • Blood donor in the last 3 month
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
Yes
Germany
 
 
NCT01535534
2011-384N-MA
No
Not Provided
Not Provided
Dr. med. Ursula Hoffmann, Universitätsmedizin Mannheim
Universitätsmedizin Mannheim
Not Provided
Principal Investigator: Ursula Hoffmann, MD Universitätsmedizin Mannheim
Study Director: Michael Behnes, MD Universitätsmedizin Mannheim
Universitätsmedizin Mannheim
November 2016